Lilly’s Investigational Triple Agonist Retatrutide Reduces OSA Severity in Phase 3 Trial
Phase 3 TRIUMPH-1 trial data show retatrutide reduced the AHI by up to 36.1 events per hour alongside substantial weight loss.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
